Biotech Values

[pcrutch]

The value of the CVR will depend on the following cash payments assuming certain regulatory milestones are met:
• $250 million cash payment upon certain US approval of Abraxane by the FDA for NSCLC (non-small cell lung cancer) with progression-free survival claim in US label; ($5.78/CVR)
• $300 million in cash upon the approval of Abraxane by the FDA for pancreatic cancer with overall survival claim in US label; ($6.93/CVR)
• $100 million cash payment upon FDA approval of Abraxane for pancreatic cancer by April 1, 2013;
• Potential cash royalty payments upon achievement of certain Abraxane and nab-pipeline products net revenue thresholds.

you can find more analysis here
http://www.pcsresearchservices.com/getattachment/c7b3d1bf-81d6-4e3f-a98b-f36d74a9b73c/ABRAXIS-CELGENE-CVRs.aspx